Evidence map›Paper›PMID 28377480›Full record

Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2017

A Phase II Study of Dovitinib in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma.

Patrick M Dillon, Gina R Petroni, Bethany J Horton, Christopher A Moskaluk, Paula M Fracasso, Michael G Douvas, Nikole Varhegyi, Snjezana Zaja-Milatovic, Christopher Y Thomas

Open access · bronzeAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 2 pooled it
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 2 syntheses or guidelines pooled it, 81 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. TROP2 Expression in Salivary Gland Adenoid Cystic Carcinoma (ACC) According to Histologic Subtype: Therapeutic Implications.Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology · 2025
    Trial
  5. Trial
  6. Phase 2 Trial of Regorafenib in Recurrent/Metastatic Adenoid Cystic Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024
    Trial
  7. Trial
  8. A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
    Trial
  9. Trial
  10. Phase II Study of Lenvatinib in Patients With Progressive, Recurrent or Metastatic Adenoid Cystic Carcinoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019
    Trial
  11. Trial
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Patrick M DillonUVA Cancer Center at the University of Virginia, Charlottesville, Virginia. PMD5B@hscmail.mcc.virginia.edu cythomas@wakehealth.edu.
Gina R PetroniUVA Cancer Center at the University of Virginia, Charlottesville, Virginia.
Bethany J HortonUVA Cancer Center at the University of Virginia, Charlottesville, Virginia.
Christopher A MoskalukUVA Cancer Center at the University of Virginia, Charlottesville, Virginia.
Paula M FracassoUVA Cancer Center at the University of Virginia, Charlottesville, Virginia.
Michael G DouvasUVA Cancer Center at the University of Virginia, Charlottesville, Virginia.
Nikole VarhegyiUVA Cancer Center at the University of Virginia, Charlottesville, Virginia.
Snjezana Zaja-MilatovicUVA Cancer Center at the University of Virginia, Charlottesville, Virginia.
Christopher Y ThomasWake Forest University, Winston-Salem, North Carolina. PMD5B@hscmail.mcc.virginia.edu cythomas@wakehealth.edu.
Wake Forest University · US

Funding

Women's Oncology Program - WONP30CA044579 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Jay William FOX · 1987 to 2026
$72.1M
NCI NIH HHS P30 CA044579
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdultAgedBenzimidazolesCarcinoma, Adenoid CysticCell ProliferationDisease-Free SurvivalFemaleHumansMaleMiddle AgedNeoplasm MetastasisNeoplasm Recurrence, LocalOncogene Proteins v-mybQuinolonesReceptor, Fibroblast Growth Factor, Type 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-oneBenzimidazolesFGFR1 protein, humanOncogene Proteins v-mybQuinolonesReceptor, Fibroblast Growth Factor, Type 1

Identifiers

PMID28377480
PMCPMC5540767
OpenAlexW2605068311

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.